ZyVersa Therapeutics FY23 EPS $(108.97)
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics reported a Fiscal Year 2023 Earnings Per Share (EPS) of $(108.97), indicating a significant loss.
March 25, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ZyVersa Therapeutics reported a significant loss in FY23 with an EPS of $(108.97).
The reported EPS of $(108.97) for ZyVersa Therapeutics indicates a significant loss for the fiscal year 2023. This substantial loss is likely to negatively impact investor sentiment and could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100